Skip to main content

Table 2 Pooled efficacy of endostatin combined with radiotherapy or chemoradiotherapy

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Endpoints Group No. of studies No. of cases Weighted pooled data (95%CI)
Response rate
ORR (%) Overall 7 271 77.2 (71.8–81.8)
ECRT 4 212 77.5 (71.4–82.7)
ERT 3 59 76.1 (63.5–85.3)
1-yr LCR (%) Overall 2 73 76.1 (65.0–84.0)
2-yr LCR (%) Overall 2 73 65.8 (54.3–75.8)
Progression-free survival
Median PFS (months) Overall 6 246 11.3
ECRT 4 212 11.2
ERT 2 34 11.8
1-yr PFS rate (%) ECRT 2 115 49.6 (40.5–58.6)
2-yr PFS rate (%) ECRT 2 115 31.7 (23.8–40.8)
3-yr PFS rate (%) ECRT 2 115 23.7 (16.7–32.5)
Overall survival
Median OS (months) Overall 4 142 18.9 (15.3–22.5)
ECRT 2 97 18.4 (9.7–27.0)
ERT 2 45 19.6 (16.2–23.1)
1-yr OS rate (%) Overall 4 154 79.4 (72.1–85.1)
ECRT 2 115 81.6 (73.5–87.7)
ERT 2 39 72.8 (55.9–85.0)
2-yr OS rate (%) Overall 3 140 59.0 (49.7–67.8)
3-yr OS rate (%) ECRT 2 115 55.7 (45.6–65.6)
ECRT 2 115 43.9 (29.8–59.0)
  1. OS Overall survival, PFS Progression-free survival, ORR Objective response rate, LCR Local control rate, ERT Endostatin combined with radiotherapy, ECRT Endostatin combined with concurrent chemoradiotherapy, yr Year